Literature DB >> 23147198

Study human pancreatic cancer in mice: how close are they?

Yuqing Zhang1, Leon Chen, Jingxuan Yang, Jason B Fleming, Paul J Chiao, Craig D Logsdon, Min Li.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer deaths and is characterized by dismal prognosis. Xenograft and genetically engineered mouse (GEM) models have recapitulated critical elements of human pancreatic cancer, providing useful tools to probe the underlying cause of cancer etiology. In this review, we provide a brief description of the common genetic lesions that occur during the development of pancreatic cancer. Next, we describe the strengths and weaknesses of these two models and highlight key discoveries each has made. Although the relative merits of GEM and xenograft pancreatic cancer mouse models are subject to debate, both systems have and will continue to yield essential insights in understanding pancreatic cancer etiology. This information is critical for the development of new methods to screen, treat, and prevent pancreatic cancer.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23147198      PMCID: PMC3538146          DOI: 10.1016/j.bbcan.2012.11.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  85 in total

1.  Mouse xenograft models vs GEM models for human cancer therapeutics.

Authors:  Ann Richmond; Yingjun Su
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

2.  Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.

Authors:  Ruben Plentz; Ji-Sun Park; Andrew D Rhim; Daniel Abravanel; Aram F Hezel; Sreenath V Sharma; Sushma Gurumurthy; Vikram Deshpande; Candia Kenific; Jeffrey Settleman; Pradip K Majumder; Ben Z Stanger; Nabeel Bardeesy
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

3.  Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts.

Authors:  Min Li; Yuqing Zhang; Uddalak Bharadwaj; Qihui Jim Zhai; Charlotte H Ahern; William E Fisher; F Charles Brunicardi; Craig D Logsdon; Changyi Chen; Qizhi Yao
Journal:  Clin Cancer Res       Date:  2009-09-15       Impact factor: 12.531

Review 4.  KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.

Authors:  John P Morris; Sam C Wang; Matthias Hebrok
Journal:  Nat Rev Cancer       Date:  2010-09-03       Impact factor: 60.716

5.  Ras activity levels control the development of pancreatic diseases.

Authors:  Baoan Ji; Lilian Tsou; Huamin Wang; Sebastian Gaiser; David Z Chang; Jaroslaw Daniluk; Yan Bi; Tobias Grote; Daniel S Longnecker; Craig D Logsdon
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

6.  Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia.

Authors:  Guanglu Shi; Liqin Zhu; Yan Sun; Ryan Bettencourt; Barbara Damsz; Ralph H Hruban; Stephen F Konieczny
Journal:  Gastroenterology       Date:  2009-01-09       Impact factor: 22.682

7.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Authors:  Lidong Wang; David G Heidt; Cheong J Lee; Huibin Yang; Craig D Logsdon; Lizhi Zhang; Eric R Fearon; Mats Ljungman; Diane M Simeone
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB.

Authors:  Yuqing Zhang; Uddalak Bharadwaj; Craig D Logsdon; Changyi Chen; Qizhi Yao; Min Li
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

9.  Distant metastasis occurs late during the genetic evolution of pancreatic cancer.

Authors:  Shinichi Yachida; Siân Jones; Ivana Bozic; Tibor Antal; Rebecca Leary; Baojin Fu; Mihoko Kamiyama; Ralph H Hruban; James R Eshleman; Martin A Nowak; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christine A Iacobuzio-Donahue
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

Review 10.  Mouse models with human immunity and their application in biomedical research.

Authors:  Baojun Zhang; Ziyuan Duan; Yong Zhao
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

View more
  6 in total

1.  Intravoxel incoherent motion analysis of abdominal organs: computation of reference parameters in a large cohort of C57Bl/6 mice and correlation to microvessel density.

Authors:  Christian Eberhardt; Moritz C Wurnig; Andrea Wirsching; Cristina Rossi; Markus Rottmar; Pinar S Özbay; Lukas Filli; Mickael Lesurtel; Andreas Boss
Journal:  MAGMA       Date:  2016-04-19       Impact factor: 2.310

Review 2.  GEMMs as preclinical models for testing pancreatic cancer therapies.

Authors:  Aarthi Gopinathan; Jennifer P Morton; Duncan I Jodrell; Owen J Sansom
Journal:  Dis Model Mech       Date:  2015-10-01       Impact factor: 5.758

3.  Monitoring pancreatic carcinogenesis by the molecular imaging of cathepsin E in vivo using confocal laser endomicroscopy.

Authors:  Hui Li; Yongdong Li; Lei Cui; Biyuan Wang; Wenli Cui; Minghua Li; Yingsheng Cheng
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

4.  Lactobacillus Attenuate the Progression of Pancreatic Cancer Promoted by Porphyromonas Gingivalis in K-rasG12D Transgenic Mice.

Authors:  Shan-Ming Chen; Li-Jin Hsu; Hsiang-Lin Lee; Ching-Pin Lin; Szu-Wei Huang; Caucasus Jun-Lin Lai; Chia-Wei Lin; Wan-Ting Chen; Yu-Jen Chen; Yu-Chien Lin; Chi-Chieh Yang; Ming-Shiou Jan
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

5.  Real-time assessment of tissue hypoxia in vivo with combined photoacoustics and high-frequency ultrasound.

Authors:  Marco Gerling; Ying Zhao; Salvatore Nania; K Jessica Norberg; Caroline S Verbeke; Benjamin Englert; Raoul V Kuiper; Asa Bergström; Moustapha Hassan; Albrecht Neesse; J Matthias Löhr; Rainer L Heuchel
Journal:  Theranostics       Date:  2014-03-18       Impact factor: 11.556

6.  Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.

Authors:  Ujjwal M Mahajan; Steffen Teller; Matthias Sendler; Raghavendra Palankar; Cindy van den Brandt; Theresa Schwaiger; Jens-Peter Kühn; Silvia Ribback; Gunnar Glöckl; Matthias Evert; Werner Weitschies; Norbert Hosten; Frank Dombrowski; Mihaela Delcea; Frank-Ulrich Weiss; Markus M Lerch; Julia Mayerle
Journal:  Gut       Date:  2016-05-12       Impact factor: 23.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.